Fernando Oswaldo Dias Rangel

TL;DR: The present study demonstrates the relative safety of intramyocardial injections of bone marrow–derived stem cells in humans with severe heart failure and the potential for improving myocardial blood flow with associated enhancement of regional and global left ventricular function.

TL;DR: The 6- and 12-month follow-up data suggest that transendocardial injection of ABMMNCs in patients with end-stage ischemic heart disease may produce a durable therapeutic effect and improve myocardial perfusion and exercise capacity.

TL;DR: In patients with acute chest pain and no ST elevation, high MPO levels upon admission to the hospital are an important tool to predict in-hospital adverse events, with an odds ratio of eight for the diagnosis of AMI.

TL;DR: Physical examination, CR and BNP had a poor performance in predicting a LAP ≥ 15 mm Hg, and using these parameters alone or in combination may lead to inaccurate estimation of hemodynamics.

TL;DR: It was possible to reduce ventricular filling pressures to significantly lower values, obtaining a significant improvement of cardiac index, systemic vascular resistance index and pulmonary artery mean pressure, by using significantly higher doses of vasodilators.